N-[4-(4-Chloro-phenyl)-thiazol-2-yl]-4-fluoro-benzamide | 313274-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(4-Chloro-phenyl)-thiazol-2-yl]-4-fluoro-benzamide
• 英文别名: N-[4-(4-chlorophenyl)thiazol-2-yl]-4-fluorobenzamide；Benzamide, N-[4-(4-chlorophenyl)-2-thiazolyl]-4-fluoro-；N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-fluorobenzamide
• CAS: 313274-50-9
• 化学式: C₁₆H₁₀ClFN₂OS
• 分子量: 332.786
• InChiKey: VLNZEFLXKYQTSC-UHFFFAOYSA-N

物化性质

• 密度：
  1.431±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-4-(4-氯苯基)噻唑 、 对氟苯甲酰氯 在 吡啶 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.5h， 以43%的产率得到N-[4-(4-Chloro-phenyl)-thiazol-2-yl]-4-fluoro-benzamide
  参考文献：
  名称：

  SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE

  摘要：

  这项发明涉及化合物、其药物组合物以及抑制鞘氨醇激酶并治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。

  公开号：

  US20070032531A1

文献信息

• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• Sphingosine Kinase Inhibitors and Methods of Their Use
  申请人：Smith Charles D.

  公开号：US20100137315A1

  公开（公告）日：2010-06-03

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  该发明涉及化合物，其制药组合物以及抑制鞘氨醇激酶和治疗或预防过度增生性疾病，炎症性疾病或血管生成性疾病的方法。
• ASPARTIC PROTEASE INHIBITORS
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP1966139B1

  公开（公告）日：2011-12-21
• Treatment Of Ischemia-Reperfusion Injury
  申请人：Smith Charles D.

  公开号：US20120122870A1

  公开（公告）日：2012-05-17

  Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.
• US8487108B2
  申请人：——

  公开号：US8487108B2

  公开（公告）日：2013-07-16